Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment

No abstract is available for this paper.

• Publication year

  2008

• Venue

  European Journal of Clinical Pharmacology

• Publication date

  2008-03-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s00228-007-0414-1PMID 18157705
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Eslicarbazepine acetate (BIA 2-093)

  2011cited by this paper
• COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) REFLECTION PAPER ON BENEFIT-RISK ASSESSMENT METHODS IN THE CONTEXT OF THE EVALUATION OF MARKETING AUTHORISATION APPLICATIONS OF MEDICINAL PRODUCTS FOR HUMAN USE DISCUSSION OF FINAL REPORT BY CHMP

  2008cited by this paper
• Eslicarbazepine Acetate: A Double‐blind, Add‐on, Placebo‐controlled Exploratory Trial in Adult Patients with Partial‐onset Seizures

  2007cited by this paper
• Effect of gender on the pharmacokinetics of eslicarbazepine acetate (BIA 2‐093), a new voltage‐gated sodium channel blocker

  2007cited by this paper
• ESLICARBAZEPINE ACETATE PHARMACOKINETICS AFTER SINGLE AND REPEATED DOSES IN HEALTHY SUBJECTS

  2005cited by this paper
• Single‐Dose and Steady‐State Pharmacokinetics of Eslicarbazepine Acetate (BIA 2–093) in Healthy Elderly and Young Subjects

  2005cited by this paper
• Safety, Tolerability, and Pharmacokinetic Profile of BIA 2‐093, a Novel Putative Antiepileptic, in a Rising Multiple‐Dose Study in Young Healthy Humans

  2004influential reference
• Safety, Tolerability and Pharmacokinetic Profile of BIA 2-093, a Novel Putative Antiepileptic Agent, during First Administration to Humans

  2003cited by this paper
• Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives.

  1999cited by this paper

• A real-world pharmacovigilance analysis of eslicarbazepine acetate using the FDA adverse events reporting system (FAERS) database from 2013 (Q4) to 2024 (Q1)

  2024cites this paper
• Efficacy, tolerability and safety of add-on third-generation antiseizure medications in treating focal seizures worldwide: a network meta-analysis of randomised, placebo-controlled trials

  2024cites this paper
• The pharmacokinetic, safety, and tolerability profiles of eslicarbazepine acetate are comparable between Korean and White subjects

  2022cites this paper
• A chiral electrokinetic chromatography method for the separation and quantitation of licarbazepine and licarbazepine acetate in pharmaceutical formulations and urine samples

  2022cites this paper
• Eslicarbazepine: Pharmacokinetics and Drug Interactions

  2022cites this paper
• Role of Human Arylacetamide Deacetylase (AADAC) on Hydrolysis of Eslicarbazepine Acetate and Effects of AADAC Genetic Polymorphisms on Hydrolase Activity

  2021influential citation
• Exposure‐safety and efficacy response relationships and population pharmacokinetics of eslicarbazepine acetate

  2018cites this paper
• Effects of eslicarbazepine on slow inactivation processes of sodium channels in dentate gyrus granule cells

  2018cites this paper
• Eslicarbazepine acetate in epilepsies with focal and secondary generalised seizures: systematic review of current evidence

  2018cites this paper
• Population Pharmacokinetics and Exposure–Response Analyses of Eslicarbazepine Acetate Efficacy and Safety in Monotherapy of Partial‐Onset Seizures

  2018cites this paper
• Safety, Tolerability and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy in Patients Aged ≥ 65 Years with Focal Seizures

  2018cites this paper
• Safety Profile of Eslicarbazepine Acetate as Add-On Therapy in Adults with Refractory Focal-Onset Seizures: From Clinical Studies to 6 Years of Post-Marketing Experience

  2017cites this paper
• Antiepileptic Drugs and Liver Disease.

  2017cites this paper
• Simultaneous UPLC-MS/MS determination of antiepileptic agents for dose adjustment.

  2017cites this paper
• Pooled efficacy and safety of eslicarbazepine acetate as add‐on treatment in patients with focal‐onset seizures: Data from four double‐blind placebo‐controlled pivotal phase III clinical studies

  2017cites this paper
• Eslicarbazepine Acetate: A New Improvement on a Classic Drug Family for the Treatment of Partial-Onset Seizures

  2017cites this paper
• The Pharmacology and Toxicology of Third-Generation Anticonvulsant Drugs

  2017cites this paper
• Prediction of efficacy for conversion from adjunctive therapy to monotherapy with eslicarbazepine acetate 800 mg once daily for partial-onset epilepsy

  2017cites this paper
• Modern management of seizures and epilepsy.

  2016cites this paper
• Eslicarbazepine acetate for the treatment of partial epilepsy

  2016cites this paper
• A Pharmacokinetic Study Comparing Eslicarbazepine Acetate Administered Orally as a Crushed or Intact Tablet in Healthy Volunteers

  2016cites this paper
• Eslicarbazepine Acetate Monotherapy: A Review in Partial-Onset Seizures

  2016cites this paper
• An Updated Overview on Therapeutic Drug Monitoring of Recent Antiepileptic Drugs

  2016cites this paper
• Therapeutic Drug Monitoring of Newer Antiepileptic Drugs

  2016cites this paper
• Update on the role of eslicarbazepine acetate in the treatment of partial-onset epilepsy

  2016cites this paper
• Carbamazepine and oxcarbazepine, but not eslicarbazepine, enhance excitatory synaptic transmission onto hippocampal CA1 pyramidal cells through an antagonist action at adenosine A1 receptors.

  2015cites this paper
• Pharmacokinetic/pharmacodynamic evaluation of eslicarbazepine for the treatment of epilepsy

  2015influential citation
• Clinical utility of eslicarbazepine: current evidence

  2015cites this paper
• 33. Eslicarbazepine Acetate

  2015cites this paper
• Pharmacological and Computational Approach to Eslicarbazepine: A Short Review

  2015cites this paper
• Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial‐onset seizures: A randomized historical‐control phase III study based in North America

  2015cites this paper
• Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action

  2015influential citation
• Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study

  2015cites this paper
• ssessing long-term effects of eslicarbazepine acetate on lipid etabolism profile , sodium values and liver function tests

  2015cites this paper
• Assessing long-term effects of eslicarbazepine acetate on lipid metabolism profile, sodium values and liver function tests.

  2015cites this paper
• Advances in anti-epileptic drug testing.

  2014cites this paper
• Eslicarbazepine acetate: an update on efficacy and safety in epilepsy.

  2014cites this paper
• Use of antiepileptic drugs in hepatic and renal disease.

  2014cites this paper
• Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial

  2014cites this paper
• Pharmacokinetics of topiramate in patients with renal impairment, end-stage renal disease undergoing hemodialysis, or hepatic impairment.

  2014cites this paper
• Eslicarbazepine Acetate: A Review of Its Use as Adjunctive Therapy in Refractory Partial-Onset Seizures

  2014cites this paper
• Effect of eslicarbazepine acetate in the corneal kindling progression and the amygdala kindling model of temporal lobe epilepsy.

  2014cites this paper
• Effects of eslicarbazepine acetate on acute and chronic latrunculin A-induced seizures and extracellular amino acid levels in the mouse hippocampus

  2014cites this paper
• Effect of eslicarbazepine acetate on the pharmacokinetics of a combined ethinylestradiol/levonorgestrel oral contraceptive in healthy women.

  2013cites this paper
• Bioequivalence of Eslicarbazepine Acetate from Two Different Sources of its Active Product Ingredient in Healthy Subjects

  2013cites this paper
• Pharmacokinetic of Antiepileptic Drugs in Patients with Hepatic or Renal Impairment

  2013cites this paper
• Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers

  2013cites this paper
• Clinical Pharmacokinetics of New-Generation Antiepileptic Drugs at the Extremes of Age: An Update

  2013cites this paper
• Efficacy and safety of eslicarbazepine acetate as add‐on treatment in patients with focal‐onset seizures: Integrated analysis of pooled data from double‐blind phase III clinical studies

  2013cites this paper
• Evaluation of neurotoxic and neuroprotective pathways affected by antiepileptic drugs in cultured hippocampal neurons.

  2013cites this paper
• Effect of repeated administration of eslicarbazepine acetate on the pharmacokinetics of simvastatin in healthy subjects.

  2013cites this paper
• Steady‐state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers

  2013cites this paper
• Acetato de eslicarbazepina: una nueva alternativa en el tratamiento de las crisis focales

  2012cites this paper
• Pharmacokinetics, Drug Interactions and Exposure-Response Relationship of Eslicarbazepine Acetate in Adult Patients with Partial-Onset Seizures

  2012influential citation
• [Eslicarbazepine acetate: a novel therapeutic alternative in the treatment of focal seizures].

  2012cites this paper
• Pharmacokinetics and drug interactions of eslicarbazepine acetate

  2012influential citation
• Evaluation of Eslicarbazepine Acetate on Cardiac Repolarization in a Thorough QT/QTc Study

  2012cites this paper
• Pharmacological Management of Epilepsy

  2012cites this paper
• Antiepileptic Drug Therapy in Children

  2012cites this paper
• Therapeutic Drug Monitoring of Classical and Newer Anticonvulsants

  2012cites this paper
• A review of eslicarbazepine acetate (Stedesa

  2012cites this paper
• New antiepileptic drugs

  2012cites this paper
• Eslicarbazepine acetate : a new promising antiepileptic agent

  2012cites this paper
• Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate

  2012cites this paper
• Therapeutic drug monitoring of newer antiepileptic drugs / Therapeutic drug monitoring bei neueren Antiepileptika

  2011cites this paper
• Hepatic UDP-Glucuronosyltransferase Is Responsible for Eslicarbazepine Glucuronidation

  2011cites this paper
• Novel Medications for Epilepsy

  2011cites this paper
• Pharmacotherapy of Epilepsy

  2011cites this paper
• Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures.

  2011cites this paper
• A Review of Eslicarbazepine Acetate for the Adjunctive Treatment of Partial-Onset Epilepsy

  2011cites this paper
• Therapeutic Drug Monitoring of Antiepileptic Medications

  2011cites this paper
• Eslicarbazepine acetate for partial-onset seizures

  2011cites this paper
• [New drugs in the treatment of adult patients with refractery epilepsy].

  2011cites this paper
• Development and validation of an enantioselective liquid-chromatography/tandem mass spectrometry method for the separation and quantification of eslicarbazepine acetate, eslicarbazepine, R-licarbazepine and oxcarbazepine in human plasma.

  2011cites this paper
• Effect of eslicarbazepine acetate and oxcarbazepine on cognition and psychomotor function in healthy volunteers.

  2010cites this paper
• Eslicarbazepine acetate: A novel agent for the adjunctive treatment of epilepsy.

  2010cites this paper
• Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Treatment in Adults with Refractory Partial-Onset Seizures: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Study. Elger C, Hal´

  2010cites this paper
• Brain Function and Anatomy in Juvenile Myoclonic Epilepsy

  2010cites this paper
• Development and validation of an HPLC-UV method for the simultaneous quantification of carbamazepine, oxcarbazepine, eslicarbazepine acetate and their main metabolites in human plasma

  2010cites this paper
• Comments on the Eslicarbazepine Acetate Section of the Article ‘Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications’

  2010cites this paper
• Pharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjects

  2010cites this paper
• Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.

  2010cites this paper
• Eslicarbazepine Acetate: A Well-Kept Secret?

  2010influential citation
• The Epilepsy Prescriber's Guide to Antiepileptic Drugs: Abbreviations

  2010cites this paper
• Pharmacokinetic interaction study between eslicarbazepine acetate and lamotrigine in healthy subjects

  2010influential citation
• When Should Corpus Callosotomy be Offered as Palliative Therapy?

  2010cites this paper
• Adverse Antiepileptic Drug Effects

  2010cites this paper
• Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy.

  2010cites this paper
• Role of eslicarbazepine in the treatment of epilepsy in adult patients with partial-onset seizures

  2010cites this paper
• Update on treatment of partial onset epilepsy: role of eslicarbazepine

  2010cites this paper
• Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications.

  2010cites this paper
• Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial‐onset seizures

  2009cites this paper
• Effect of eslicarbazepine acetate on the pharmacokinetics of digoxin in healthy subjects

  2009cites this paper
• Eslicarbazepine acetate: a new option for the treatment of focal epilepsy

  2009cites this paper
• Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions.

  2009cites this paper
• Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions

  2009cites this paper
• Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures

  2009cites this paper
• Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial‐onset seizures: A randomized, double‐blind, placebo‐controlled, parallel‐group phase III study

  2009influential citation
• Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX).

  2009cites this paper
• Eslicarbazepine Acetate

  2009cites this paper